Faeth Therapeutics, Inc.

NASDAQ:FTH

Biotechnology

Healthcare
$8.72 +5.01%

+$1.43 today

Market cap
$224.79M
Beta
-0.31
P/E (TTM)
-0.2
EPS (TTM)
-$34.65
52W Low $7.21High $37.90

Volume 0.33M

Average 0.12M

FTH Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Faeth Therapeutics, Inc.NASDAQ: FTH

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense remains negative

Q2 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0.

Context

  • Income tax expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Income Tax Expense vs competitors

How FTH compares with its peers on the latest reported figures

  • FTH's LTM Jun 2026 income tax expense of $0 is the 3rd highest of the 10 companies compared; the peer median is $0.
FTH Competitors Peer median
Income Tax Expense for FTH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PBYIPuma Biotechnology, Inc.LTM Mar 2026$4.7M +177.1%+117.3%2.1%
KURAKura Oncology, Inc.LTM Mar 2026$79K -96.5%—0.1%
FTHFaeth Therapeutics, Inc.LTM Jun 2026$0 ———
RLAYRelay Therapeutics, Inc.LTM Jun 2026$0 ——0.0%
NUVBNuvation Bio Inc.LTM Jun 2026$0 ——0.0%
VSTMVerastem, Inc.LTM Mar 2026$0 -100.0%—0.0%
JANXJanux Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$0 ——0.0%
BOLDBoundless Bio, Inc.LTM Mar 2026$0 ———
TNGXTango Therapeutics, Inc.LTM Sep 2026-$53K -149.1%-58.0%—
Peer median (excluding FTH) $0-98.2%+29.7%0.0%

Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue685K1.81M571K551K0
Gross Profit(685K)(1.81M)(571K)(551K)0
Gross Margin—————
Research & Development21.66M29.58M18.3M18.63M10.96M
Selling, General & Admin15.14M17.73M18.77M12.49M11.33M
Operating Expenses36.8M47.31M36.49M31.11M22.29M
Depreciation & Amortization685K1.81M3.68M551K139K
EBITDA(35.44M)(46.56M)(33.39M)(29.52M)(20.91M)
EBITDA Margin—————
Operating Income(37.48M)(49.12M)(37.06M)(31.66M)(22.29M)
Operating Margin—————
Interest Income800K1.78M3.62M2.55M1.24M
Interest Expense670K219K144K90K32K
Other Income / Expenses688K532K2.96M1.51M1.2M
Income Before Tax(36.79M)(48.59M)(34.1M)(30.16M)(21.09M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(36.79M)(48.59M)(34.1M)(30.16M)(21.09M)
Net Margin—————
EPS (Basic)(26.56)(31.65)(24.40)(24.01)(16.72)
EPS (Diluted)(26.56)(31.65)(24.40)(24.01)(16.72)
Weighted Avg Shares1.39M1.54M1.4M1.26M1.26M
Weighted Avg Shares (Diluted)1.39M1.54M1.4M1.26M1.26M

Faeth Therapeutics, Inc.

NASDAQ:FTH

Intrinsic Alpha fair value

Locked

Current Price

$8.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.